Michele Menotta

Title: Michele Menotta: Innovator in Ataxia Telangiectasia Treatment

Introduction

Michele Menotta is a notable inventor based in Fano, Italy. He has made significant contributions to the field of medical research, particularly in the treatment of Ataxia Telangiectasia (A-T). His innovative approach has the potential to improve the quality of life for patients affected by this condition.

Latest Patents

Michele Menotta holds a patent for a method of evaluating the response of Ataxia Telangiectasia patients to glucocorticoids treatment. The patent describes a novel procedure that involves the qualitative and/or quantitative identification of a specific mRNA variant of the ATM gene in the blood of patients. This mRNA variant is produced by non-canonical splicing induced by glucocorticoids. The invention demonstrates that the expression of this mRNA variant is present in the blood of patients who respond positively to glucocorticoid treatment. This advancement could lead to more effective treatment strategies for A-T patients.

Career Highlights

Michele Menotta is associated with Erydel S.p.a., where he continues to work on innovative solutions in the medical field. His dedication to research and development has positioned him as a key figure in the advancement of treatments for rare diseases.

Collaborations

Michele collaborates with talented professionals such as Mauro Magnani and Sara Biagiotti. Their combined expertise contributes to the ongoing research and development efforts at Erydel S.p.a.

Conclusion

Michele Menotta's work in evaluating treatments for Ataxia Telangiectasia showcases his commitment to improving patient outcomes. His innovative patent and collaboration with skilled colleagues highlight the importance of research in the medical field.